On July 21, 2026, Novitium Pharma announced the approval of its generic drug application ANDA218495, a development likely to drive immediate revenue growth and strengthen its standing in the generic market. The authorization positions Novitium to compete aggressively against branded competitors, potentially reshaping market shares and optimizing its pricing strategy.